home > drug information > Remicade

Remicade

Company: Centocor
Approval Status: Approved February 2002
Treatment for: Rheumatoid arthritis
Areas: Musculoskeletal; Rheumatology

General Information

Other Useful Resources

Remicade, administered through intravenous infusion, has been approved for improvement in physical function for individuals suffering from rheumatoid arthritis (RA). This recent approval is in addition to previous approvals for inhibiting the progression of structural damage and for reducing signs and symptoms of RA. The drug indicated for the treatment of Crohn's disease as well and is the only biologic drug approved for these two conditions. Remicade is also the first drug approved for this most recent indication. For RA treatment, Remicade is to be used in combination with methotrexate, a standard treatment for RA. The combination treatment is given six to eight times per year.

RA is a debilitating, chronic disease that affects more than two million Americans. This autoimmune disease causes the body's immune system to attack multiple joints, leading to pain, swelling and eventually to irreversile joint damage.

< back to top

Clinical Results

The approval of Remicade for improvement in physical function compromised by RA is supported by a two year double-blind, placebo-controlled study that evaluated changes in physical function due to treatment with Remicade and methotrexate, compared to methotrexate alone. The primary endpoint of the trials, which included 428 subjects, was the changes in physical function and disability from baseline to study end.

Those who received Remicade and methotrexate experienced statistically significant improvement compared to those adminstered only methotrexate. Improvements were evident after 54 weeks of treatment and were sustained through out the entire 102 weeks.

< back to top

Side Effects

Adverse events associated with the use of Remicade may include (but are not limited to) the following:

Upper respiratory infection
Cough
Sinusitis
Headache
Rash
Abdominal pain

< back to top

Mechanism of Action

Remicade (infliximab) is a chimeric monoclonal antibody that targets and binds to tumor necrosis factor alpha (TNF-a). TNF-a is a key factor in regulating the inflammation in RA. By inactivating TNF-a, the inflammatory process is significantly diminished from the start.

< back to top

Additional Information

For additional information on Remicade, please visit Remicade.

< back to top

The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Remicade

General Information

Clinical Results

Side Effects

Mechanism of Action

Additional Information

Features:

Medical Toolbar

PDA Medical Dictionary